Royalty Pharma (RPRX) is set to report results on Thursday

Royalty Pharma (NASDAQ:RPRX – Get Rating) will announce its results before the market opens on Thursday, May 5. Analysts expect the company to report earnings of $0.73 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX – Get Rating) last reported results on Tuesday, February 15. The biopharmaceutical company reported earnings per share (EPS) of $0.80 for the quarter, beating consensus analyst estimates of $0.79 by $0.01. The company posted revenue of $543.00 million for the quarter, versus analyst estimates of $543.50 million. Royalty Pharma posted a net margin of 27.07% and a return on equity of 17.29%. In the same quarter a year earlier, the company posted EPS of $0.28. On average, analysts expect Royalty Pharma to post EPS of $3 for the current fiscal year and EPS of $3 for the next fiscal year.

Royalty Pharma shares opened at $42.99 on Thursday. The company has a market capitalization of $26.10 billion, a PE ratio of 42.15, a price-to-earnings growth ratio of 1.25 and a beta of 0.74. The company’s 50-day simple moving average is $39.98 and its 200-day simple moving average is $39.65. The company has a debt ratio of 0.69, a quick ratio of 16.81 and a current ratio of 16.81. Royalty Pharma has a 1-year low of $34.86 and a 1-year high of $47.10.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 15. Shareholders of record on Friday, May 20 will receive a dividend of $0.19. The ex-dividend date is Thursday, May 19. This represents a dividend of $0.76 on an annualized basis and a dividend yield of 1.77%. Royalty Pharma’s dividend payout ratio (DPR) is currently 74.51%.

Several equity research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upgraded Royalty Pharma shares from a “neutral” rating to an “overweight” rating and set a price target of $50.00 on the stock in a Thursday, April 14 research note . They noted that the move was a review call. took over Royalty Pharma stock coverage in a Thursday, March 31 research note. They have placed a “holding” rating on the stock. Zacks Investment Research downgraded shares of Royalty Pharma from a “hold” rating to a “sell” rating in a Wednesday, Jan. 26 research note. Morgan Stanley upgraded Royalty Pharma shares from an “equal weight” rating to an “overweight” rating and raised its price target for the stock from $46.00 to $48.00 in a rating of research from Wednesday, April 6. Finally, Goldman Sachs Group assumed coverage for Royalty Pharma shares in a research note on Wednesday. They set a “buy” rating and a price target of $56.00 on the stock. One research analyst rated the stock with a sell rating, one issued a hold rating and five assigned the company a buy rating. According to data from, Royalty Pharma has an average rating of “Buy” and an average target price of $48.83.

Separately, director Henry A. Fernandez acquired 32,500 shares of the company in a transaction dated Thursday, February 24. The shares were acquired at an average cost of $37.49 per share, for a total transaction of $1,218,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available via this link. Additionally, director Rory B. Riggs sold 129,222 shares in a trade that took place on Friday, March 18. The shares were sold at an average price of $39.55, for a total transaction of $5,110,730.10. The disclosure of this sale can be found here. Insiders sold 229,089 shares of the company valued at $8,982,936 during the last quarter. Insiders hold 25.86% of the shares of the company.

Hedge funds have recently increased or reduced their holdings in the stock. LPL Financial LLC acquired a new stake in Royalty Pharma during the fourth quarter valued at approximately $308,000. Stifel Financial Corp increased its stake in Royalty Pharma by 117.1% during the fourth quarter. Stifel Financial Corp now owns 12,041 shares of the biopharmaceutical company valued at $480,000 after buying an additional 6,495 shares in the last quarter. OLD Mission Capital LLC purchased a new stake in shares of Royalty Pharma in Q3, valued at approximately $1,211,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Royalty Pharma in Q4, valued at approximately $2,443,000. Finally, Privium Fund Management UK Ltd purchased a new equity stake in Royalty Pharma in Q4, valued at approximately $9,739,000. 43.78% of the shares are held by institutional investors and hedge funds.

About Royalty Pharma (Get a rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. She is also involved in the identification, evaluation and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and non-profit organizations, small and medium biotech companies and pharmaceutical companies.

See also

Earnings History for Royalty Pharma (NASDAQ:RPRX)

Get news and reviews for Royalty Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Royalty Pharma and related companies with’s FREE daily newsletter.

Comments are closed.